Alternatives · ranked by WeighScore
Alternatives to Breeze Meds
Breeze Meds grades C (72.4/100), #43 of 43 on our scorecard. Here are the other providers we've graded on the same six dimensions — ranked by WeighScore, highest first.
You're comparing against
Breeze Meds →Our top-graded alternative
CoreAge Rx leads the full scorecard.
Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
More alternatives, ranked
High-disclosure, high-oversight compounded program with the cleanest verification signals.
An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
The widest formulation spread on the board — injection, drops, lozenges and a daily oral pill, plus a real brand Zepbound lane.
A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.
Lowest semaglutide sticker on the board ($93) paired with some brand-name access and LegitScript verification.
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
Bottom-quartile pricing on both molecules under one flat membership, shipped free nationwide — a strong-value pick sitting just behind the top tier.
A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
An established pharmacy operator with steady mid-market pricing and a broad catalog.
A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.
Sub-$100 semaglutide and $149 tirzepatide — both molecules, verified and nationwide.
Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
A LegitScript-certified, HIPAA telehealth with one of the deepest published catalogs on the board — compounded semaglutide and tirzepatide (oral and microdosed routes included) alongside PT-141, intranasal NAD+, and a long recovery/GH peptide bench — with compounded GLP-1 starting from $49/mo on an annual plan.
The cheapest both-molecule pairing on the board ($100/$133) from a LegitScript-verified operator.
One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.
A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
Low both-molecule pricing ($117/$159) and verified — but only 36 states.
Mid-value both-molecule pricing ($130/$163), verified, and nationwide.
Among the lowest compounded-semaglutide pricing, with some brand-name access.
Tight both-molecule spread ($133/$166), verified and nationwide.
Among the cheapest both-molecule pairings ($99/$139), nationwide — but not LegitScript-listed.
A both-molecule compounded program that publishes its prices up front — semaglutide $199/mo, tirzepatide $299/mo — across a 50-state clinician network, with an optional coaching-plus-labs membership and a NAD+/microdosing menu on the side.
Cheap semaglutide ($119) but a steeper tirzepatide step-up ($229); verified, nationwide.
Round mid-market pricing ($149/$199), verified and available nationwide.
Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.
Aggressive identical pricing on both molecules, wrapped in a coaching-first program.
Round-$100 semaglutide nationwide, though tirzepatide runs $175 and it isn't verified.
Verified and nationwide, but priced in the upper-mid band ($152/$246).
One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
Low-ish both-molecule pricing ($117/$196), nationwide — but unverified.
The same molecule as a lozenge or an injection at the same price — the one place here where the needle is genuinely optional.
Mid-value both-molecule pricing ($135/$199), nationwide, though not verified.
Mass-market app-first program with nationwide reach and consumer-grade polish.
Publishes its price at every single dose, so what a titrated dose costs is knowable on day one.
Both molecules across 40 states, but upper-mid pricing and no verification listing.
A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.
The Bodybuilding.com fitness brand's new compounded-telehealth arm — genuinely cheap GLP-1 bundles (sema and tirz both down to $139/mo on the annual plan) sitting on top of a deep sermorelin/NAD+/peptide bench — solid value and honest FDA labeling, but brand-new, compounded, and final-sale, so it lands as a value runner-up rather than a top pick.
A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.
Brand Wegovy, Ozempic or Mounjaro when clinically appropriate, with unlimited round-the-clock clinical contact.
The cheapest published prices on the board, sold as a package with no membership fee.
Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.